The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: A retrospective analysis of 50 studies

References

• Costa F. V. Compliance with antihypertensive treatment. Clin Exp Hypertens 1996; 18: 463–472
   PubMed Web of Science ®Google Scholar
• Nunes M. I. The relationship between quality of life and adherence to treatment. Curr Hypertens Rep 2001; 3: 462–465
   PubMedGoogle Scholar
• Bloom B. S. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671–681
   PubMed Web of Science ®Google Scholar
• Marques‐Vidal P., Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the rule of halves still valid?. J Hum Hypertens 1997; 11: 213–220
   PubMed Web of Science ®Google Scholar
• Wienen W., Entzeroth M., van Meel J. C. A., Stangier J., Busch U., Ebner T., et al. A review on telmisartan: A novel, long‐acting angiotensin II‐receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127–156
   Google Scholar
• Stangier J., Su C. A. P. F., Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149–167
   PubMed Web of Science ®Google Scholar
• Sharpe M., Jarvis B., Goa K. L. Telmisartan: A review of its use in hypertension. Drugs 2001; 61: 1501–1529
   PubMed Web of Science ®Google Scholar
• Stangier J., Su C. A., van Heiningen P. N., Meinick T., van Lier J. J., de Bruin H., et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol 2001; 38: 672–685
   PubMed Web of Science ®Google Scholar
• Battershill A. J., Scott L. J. Telmisartan: A review of its use in the management of hypertension. Drugs 2006; 66: 51–83
   PubMed Web of Science ®Google Scholar
• White W. B., Punzi H. A., Murwin D., Koval S. E., Davidai G., Neutel J. M. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J Clin Hypertens 2006; 8: 626–633
   PubMedGoogle Scholar
• Sharma A. M., Davidson J., Koval S., Lacourciere Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: The SMOOTH study. Cardiovasc Diabetol 2007; 6: 28
   PubMed Web of Science ®Google Scholar
• Michel M. C., Bohner H., Köster J., Schäfers R., Heemann U. Safety of telmisartan in patients with arterial hypertension: An open‐label observational study. Drug Saf 2004; 27: 335–344
   PubMed Web of Science ®Google Scholar
• Keene L. C., Davies P. H. Drug‐related erectile dysfunction. Adverse Drug React Toxicol Rev 1999; 18: 5–24
   PubMedGoogle Scholar
• Overlack A. ACE inhibitor‐induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf 1996; 15: 72–78
   PubMed Web of Science ®Google Scholar
• Vleeming W., van Amsterdam J. G., Stricker B. H., de Wildt D. J. ACE inhibitor‐induced angioedema. Incidence, prevention and management. Drug Saf 1998; 18: 171–188
   PubMed Web of Science ®Google Scholar
• Prichard B. N., Owens C. W., Woolf A. S. Adverse reactions to diuretics. Eur Heart J 1992; 13(Suppl G)96–103
   PubMedGoogle Scholar
• No authors listed. Angiotensin II receptor antagonists and heart failure: Angiotensin‐converting‐enzyme inhibitors remain the first‐line option. Prescrire Int 2005; 14: 180–186
   PubMedGoogle Scholar
• Pfeffer M. A., McMurray J. J., Velazquez E. J., Rouleau J. L., Kober L., Maggioni A. P., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906, Erratum in N Engl J Med 2004; 350: 203
   PubMed Web of Science ®Google Scholar
• Dickstein K., Kjekshus J., OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Tril in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–760
   PubMed Web of Science ®Google Scholar
• Gillespie L. D., Gillespie W. J., Robertson M. C., Lamb S. E., Cumming R. G., Rowe B. H. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 2001; CD000340
   Google Scholar
• Papademetriou V. Diuretics in hypertension: Clinical experiences. Eur Heart J 1992; 13(Suppl G)92–95
   PubMedGoogle Scholar
• Stangier J., Su C. A., Hendricks M. G., van Lier J. J., Sollie F. A., Oosterhuis B., et al. The effect of telmisartan on the steady‐state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol 2000; 40: 1373–1379
   PubMed Web of Science ®Google Scholar
• Weinberger M. H. Diuretics and their side effects. Dilemma in the treatment of hypertension. Hypertension 1988; 11: 16–20
   Web of Science ®Google Scholar
• Weinberger M. H. Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects. J Cardiovasc Pharmacol 1989; 13: S1–S4
   Web of Science ®Google Scholar
• Iwanaga T., Sato M., Maeda T., Ogihara T., Tamai I. Concentration‐dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320: 211–217
   PubMed Web of Science ®Google Scholar
• Viazzi F., Leoncini G., Ratto E., Falqui V., Parodi A., Conti N., et al. Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am J Hypertens 2007; 20: 1276–1282
   PubMed Web of Science ®Google Scholar
• Coronel F., Cigarran S., Garcia‐Mena M., Herrero J. A., Calvo N., Perez‐Flores I. Irbesartan in hypertensive non‐diabetic advanced chronic kidney disease. Comparative study with ACEI. Nefrologia 2008; 28: 56–60
   PubMed Web of Science ®Google Scholar
• Reid J. L. Molecular‐specific effects of angiotensin II antagonists: Clinical relevance to treating hypertension?. J Renin Angiotensin Aldosterone Syst 2005; 6: 15–24
   PubMed Web of Science ®Google Scholar
• Cohn J. N., Tognoni G., Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675
   PubMed Web of Science ®Google Scholar